ProKidney (NASDAQ:PROK) Director Sells $1,190,062.32 in Stock

ProKidney Corp. (NASDAQ:PROK) Director Brian Jg Pereira sold 502,136 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $2.37, for a total value of $1,190,062.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Brian Jg Pereira also recently made the following trade(s):

• On Wednesday, November 12th, Brian Jg Pereira sold 255,026 shares of ProKidney stock. The shares were sold at an average price of $2.72, for a total value of $693,670.72.

ProKidney Stock Performance

Shares of NASDAQ PROK traded up $0.13 during mid-day trading on Friday, hitting $2.41. 1,335,185 shares of the stock traded hands, compared to its average volume of 4,689,348. The company has a market cap of $709.22 million, a price-to-earnings ratio of -4.38 and a beta of 1.75. The stock has a fifty day moving average price of $2.81 and a 200-day moving average price of $2.12. ProKidney Corp. has a 52 week low of $0.46 and a 52 week high of $7.13.

ProKidney (NASDAQ:PROK) last announced its earnings results on Monday, November 10th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.04 million. As a group, sell-side analysts predict that ProKidney Corp. will post -0.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on PROK. Zacks Research cut ProKidney from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of ProKidney in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $6.25.

Hedge Funds Weigh In On ProKidney

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Zullo Investment Group Inc. purchased a new stake in shares of ProKidney during the 3rd quarter valued at about $28,000. Catalyst Funds Management Pty Ltd bought a new position in ProKidney during the second quarter valued at approximately $36,000. AQR Capital Management LLC boosted its holdings in ProKidney by 106.4% in the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock worth $46,000 after purchasing an additional 27,098 shares during the last quarter. Deutsche Bank AG grew its position in ProKidney by 49.4% in the 1st quarter. Deutsche Bank AG now owns 86,337 shares of the company’s stock worth $76,000 after purchasing an additional 28,546 shares during the period. Finally, Jefferies Financial Group Inc. bought a new stake in ProKidney in the 3rd quarter worth approximately $158,000. Institutional investors own 51.59% of the company’s stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.